Get started
Author

Uzma A. Khan

Observed names: U Khan, U. A. Khan, U. Khan, U.A. Khan, Uzma Khan, Uzma. Khan.
ORCID: 0000-0002-3602-5950
Observed ORCID: 0000-0002-3602-5950
OpenAlex ID: A5011488720
Engaging the private sector to increase tuberculosis case detection: an impact evaluation study
2012 · Aamir J Khan, Saira Khowaja, et al. · The Lancet Infectious Diseases · 140
Co‐morbid medical and psychiatric illness and substance abuse in HCV‐infected and uninfected veterans
2007 · A. A. Butt, U. A. Khan, et al. · Journal of Viral Hepatitis · 104
Plasma C-Reactive Protein Levels Are Associated With Improved Outcome in ARDS
2009 · Ednan K. Bajwa, Uzma A. Khan, et al. · CHEST Journal · 81
PDF
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
2020 · Molly F. Franke, Palwasha Khan, et al. · American Journal of Respiratory and Critical Care Medicine · 62
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
2022 · Catherine Hewison, Uzma Khan, et al. · Clinical Infectious Diseases · 58
PDF
Tuberculosis control and care in the era of COVID-19
2020 · Amyn A Malik, Nauman Safdar, et al. · Health Policy and Planning · 57
PDF
Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan
2011 · F. Qazi, U. Khan, et al. · The International Journal of Tuberculosis and Lung Disease · 53
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
2019 · Uzma Khan, Helena Huerga, et al. · BMC Infectious Diseases · 48
PDF
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
2022 · Helena Huerga, Uzma Khan, et al. · Clinical Infectious Diseases · 45
PDF
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
2025 · Lorenzo Guglielmetti, Uzma Khan, et al. · The Lancet Respiratory Medicine · 42
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation
2023 · Ellen Mooneyhan, Huma Qureshi, et al. · Journal of Viral Hepatitis · 37
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
2021 · L. Guglielmetti, E. Ardizzoni, et al. · Trials · 35
PDF
Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers
2009 · Adeel A. Butt, Uzma A. Khan, et al. · HIV Clinical Trials · 29
PDF
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs
2023 · Ismat Lotia Farrukh, Nathalie Lachenal, et al. · Clinical Infectious Diseases · 23
PDF
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
2023 · Letizia Trevisi, Miguel A. Hernán, et al. · American Journal of Respiratory and Critical Care Medicine · 23
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis
2019 · Kwonjune J Seung, Palwasha Khan, et al. · Clinical Infectious Diseases · 21
Comorbidities and Their Impact on Mortality in HCV and HCV-HIV–coinfected Persons on Dialysis
2008 · Adeel A. Butt, Uzma A. Khan, et al. · Journal of Clinical Gastroenterology · 20
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
2023 · S. B. Patil, M. Tamirat, et al. · Trials · 18
PDF
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
2023 · M. L. Rich, U. Khan, et al. · The International Journal of Tuberculosis and Lung Disease · 16
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
2021 · Palwasha Y. Khan, Molly F. Franke, et al. · European Respiratory Journal · 15
Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus
2008 · Adeel A. Butt, Joel Tsevat, et al. · International Journal of Infectious Diseases · 15
Impact of scaling up Xpert® MTB/RIF testing for the detection of rifampicin-resistant TB cases in Karachi, Pakistan
2018 · W. M. Awan, S. M. A. Zaidi, et al. · The International Journal of Tuberculosis and Lung Disease · 14
PDF
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB
2020 · V. Cox, L. McKenna, et al. · The International Journal of Tuberculosis and Lung Disease · 12
The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort
2024 · Uzma Khan, Michael Rich, et al. · Clinical Infectious Diseases · 11
PDF
Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up
2023 · Sara M Sauer, Carole D Mitnick, et al. · Clinical Infectious Diseases · 11
PDF
Works count: 49
Citation count: 1,116
H-index: 18
I10-index: 29
Year
Topic
Type